Barriers and facilitators to disease-modifying antirheumatic drug use in patients with inflammatory rheumatic diseases: a qualitative theory-based study

被引:27
作者
Voshaar, Marieke [1 ]
Vriezekolk, Johanna [2 ]
van Dulmen, Sandra [3 ,4 ,5 ]
van den Bemt, Bart [6 ,7 ,8 ]
van de Laar, Mart [9 ,10 ]
机构
[1] Univ Twente, Dept Psychol Hlth & Technol, Enschede, Netherlands
[2] Sint Maartensklin, Dept Rheumatol, Nijmegen, Netherlands
[3] NIVEL Netherlands Inst Hlth Serv Res, Utrecht, Netherlands
[4] Radboud Univ Nijmegen, Dept Primary & Community Care, Med Ctr, Nijmegen, Netherlands
[5] Univ Coll Southeast Norway, Fac Hlth Sci, Drammen, Norway
[6] Sint Maartensklin, Dept Pharm, Nijmegen, Netherlands
[7] Radboudumc, Dept Pharm, Nijmegen, Netherlands
[8] Maastricht Univ, Dept Clin Pharm & Toxicol, Med Ctr, Maastricht, Netherlands
[9] Med Spectrum Twente, Arthritis Ctr, Enschede, Netherlands
[10] Univ Twente, Enschede, Netherlands
关键词
Medication adherence; Inflammatory arthritis; Theoretical Domains Framework; Disease modifying anti rheumatic drugs; Adherence; Non-adherence; Rheumatoid arthritis; MEDICATION ADHERENCE; ARTHRITIS PATIENTS; SELF-EFFICACY; RECOMMENDATIONS; TARGET; DETERMINANTS; PEOPLE; DELAY;
D O I
10.1186/s12891-016-1289-z
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
Background: Although disease-modifying anti-rheumatic drugs (DMARDs) are the cornerstone of treatment for inflammatory rheumatic diseases, medication adherence to DMARDs is often suboptimal. Effective interventions to improve adherence to DMARDs are lacking, and new targets are needed to improve adherence. The aim of the present study was to explore patients' barriers and facilitators of optimal DMARD use. These factors might be used as targets for adherence interventions. Methods: In a mixed method study design, patients (n = 120) with inflammatory arthritis (IA) completed a questionnaire based on an existing adapted Theoretical Domains Framework (TDF) to identify facilitators and barriers of DMARD use. A subgroup of these patients (n = 21) participated in focus groups to provide insights into their facilitators and barriers. The answers to the questionnaires and responses of the focus groups were thematically coded by three researchers independently and subsequently categorized. Results: The barriers and facilitators that were reported by IA patients presented large inter-individual variations. The identified barriers and facilitators could be captured in the following domains based on an adapted TDF: (i) knowledge, (ii) emotions, (iii) attention, memory, and decision processes, (iv) social influences, (v) beliefs about capability, (vi) beliefs about consequences, (vii) motivation and goals, (viii) goal conflict, (ix) environmental context and resources, and (x) skills. Conclusions: Patients with IA have a variety of barriers and facilitators with regard to their DMARD use. All of these barriers and facilitators could be categorized into adapted domains of the TDF. Interventions that address individual facilitators and barriers, based on capability, opportunity, and motivation, are needed to develop strategies for medication adherence that are tailored to individual patient needs.
引用
收藏
页数:12
相关论文
共 44 条
  • [1] THE THEORY OF PLANNED BEHAVIOR
    AJZEN, I
    [J]. ORGANIZATIONAL BEHAVIOR AND HUMAN DECISION PROCESSES, 1991, 50 (02) : 179 - 211
  • [2] Bandura A., 1986, Social foundations of thought and action: a social cognitive theory, P23
  • [3] Boyatzis R., 1998, TRANSFORMING QUALITA
  • [4] Determinants of compliance with medication in patients with rheumatoid arthritis: the importance of self-efficacy expectations
    Brus, H
    van de Laar, M
    Taal, E
    Rasker, J
    Wiegman, O
    [J]. PATIENT EDUCATION AND COUNSELING, 1999, 36 (01) : 57 - 64
  • [5] Delay in Receiving Rheumatology Care Leads to Long-Term Harm
    Bykerk, Vivian
    Emery, Paul
    [J]. ARTHRITIS AND RHEUMATISM, 2010, 62 (12): : 3519 - 3521
  • [6] Treatment adherence and clinical outcome in systemic lupus erythematosus
    Chambers, S. A.
    Rahman, A.
    Isenberg, D. A.
    [J]. RHEUMATOLOGY, 2007, 46 (06) : 895 - 898
  • [7] Adherence to treatment in systemic lupus erythematosus patients
    Costedoat-Chalumeau, Nathalie
    Pouchot, Jacques
    Guettrot-Imbert, Gaelle
    Le Guern, Veronique
    Leroux, Gaelle
    Marra, Donata
    Morel, Nathalie
    Piette, Jean-Charles
    [J]. BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2013, 27 (03): : 329 - 340
  • [8] Darmawan J, 2003, J RHEUMATOL, V30, P50
  • [9] de Achaval Sofia, 2010, Int J Clin Rheumtol, V5, P313
  • [10] DOYLE DV, 1993, BRIT J RHEUMATOL, V32, P614